Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain.

Mareque MaríaM ClimenteE Martinez-MoragonA PadillaI OyagüezC TouronC TorresA Martinez

Published in: The Journal of asthma : official journal of the Association for the Care of Asthma (2022)

Benralizumab can be considered as a dominant treatment alternative vs. other biologic drugs for the treatment of uncontrolled severe eosinophilic asthma patients in Spain.

Keyphrases

chronic obstructive pulmonary disease
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
rheumatoid arthritis
early onset
allergic rhinitis
drug induced
cystic fibrosis
patient reported outcomes
replacement therapy
atopic dermatitis